Hyalinising clear cell carcinoma is a rare, usually low-grade salivary gland cancer that most often appears in the palate or tongue base. An EWSR1 gene test confirms the diagnosis. Surgery with clear margins usually controls it well.
What is hyalinising clear cell carcinoma of the salivary gland?
Hyalinising clear cell carcinoma (HCCC) is a rare, usually low-grade cancer of the salivary glands. It most often grows in the minor salivary glands, the hundreds of tiny glands scattered through the lining of the mouth and throat. Common sites include the palate, the base of the tongue and the nasopharynx, the space behind the nose.
The name describes the tumour’s appearance under the microscope. Many of its cells have clear cytoplasm, and they grow in cords and nests within dense, glassy, scar-like tissue called hyalinised stroma. In the most recent World Health Organization (WHO) classification, the tumour is called simply clear cell carcinoma of the salivary gland.
For many years, HCCC was a diagnosis of exclusion, made only after ruling out other tumours with clear cells. In 2011, researchers discovered that most cases carry a specific gene fusion, EWSR1::ATF1 (Antonescu et al., 2011). This test now allows pathologists to identify the tumour with confidence (Weinreb, 2013).
HCCC usually appears as a slow-growing, painless lump in the mouth. The main treatment is surgery with clear margins. Radiotherapy is added for higher-risk tumours. The outlook is usually good, although some tumours return locally and a minority spread to lymph nodes or further.
1. Key facts at a glance
2. Types
Low-grade and high-grade HCCC
A study of 87 tumours from seven centres proposed a two-tier grading system (Xu et al., 2025).
Tumours that look similar
Distinguishing HCCC from mucoepidermoid carcinoma is particularly important, because grading systems for the latter can make HCCC look more aggressive than it is, which may lead to overtreatment (Antonescu et al., 2011).
The salivary glands
Tumours of the minor salivary glands are more likely to be cancerous than those of the large parotid glands. HCCC is one of the cancers that shows a strong preference for these small glands: in the Xu series, about nine in ten tumours arose in minor glands.
How molecular testing changed the picture
Before the gene fusion was discovered, pathologists could only diagnose HCCC by excluding other clear cell tumours. This was difficult, and some tumours were labelled as more aggressive types. The finding of the EWSR1::ATF1 fusion changed this. It is present in the great majority of cases and absent from most tumours that look similar under the microscope (Antonescu et al., 2011).
Molecular testing also revealed that HCCC can show a wider range of appearances than first thought. Tumours with recurrence, spread or high-grade features have been confirmed as HCCC by this test (Weinreb, 2013). Today, the test is a routine part of diagnosis in specialist centres.
3. Causes and risk factors
The cause of HCCC is not known.
4. How does it look
In the mouth
In a review of 254 cases, the most common presentation was a painless mass on the palate. Symptoms had been present for anything from one week to six years (Desai et al., 2022).
On scans
Under the microscope
In the Xu study, 97% of tumours tested had an EWSR1 rearrangement, and nearly half showed perineural invasion, meaning growth along nerves.
5. Symptoms
Common symptoms
- A painless lump in the roof of the mouth or another part of the mouth
- Swelling at the base of the tongue
- A feeling of something in the throat
Less common symptoms
When to seek medical advice
See your doctor or dentist about any lump in the mouth or throat lasting more than three weeks, especially if it is growing.
6. Diagnosis
Staging follows the TNM system for the site where the tumour started, such as the oral cavity or pharynx.
7. Treatment
Surgery
Radiotherapy
Chemotherapy and targeted therapy
Treatment by situation
Recovery after surgery
Eating and speaking after palate surgery
When part of the palate is removed, there can be an opening between the mouth and the nose. This can make speech sound nasal and allow food or liquid into the nose. A dental specialist called a prosthodontist can make a plate, called an obturator, that closes the gap.
Many people find that their speech and eating return close to normal with a well-fitting obturator. Alternatively, surgeons may close the defect with tissue from elsewhere in the body.
Side effects
8. Outlook (prognosis)
The survival figures come from Xu et al. (2025), and the recurrence and spread figures from Desai et al. (2022).
Factors affecting the outlook
The relatively low disease-free survival shows that recurrence is not rare, even though most patients survive their disease. Long-term follow-up is therefore important.
9. Follow-up
10. Living with hyalinising clear cell carcinoma
- Visit your dentist before and regularly after radiotherapy
- Use fluoride products and saliva substitutes if your mouth is dry
- Work with speech and swallowing therapists after surgery
- Wear and care for your palatal prosthesis as advised
- Stop smoking and limit alcohol to support healing
- Report new lumps, pain or numbness promptly
- Seek support from head and neck cancer charities
11. Frequently asked questions
12. Questions to ask your care team
- Has the diagnosis been confirmed by EWSR1 testing?
- Is my tumour low grade or high grade?
- Were the margins clear?
- Do I need radiotherapy or neck treatment?
- How will treatment affect my speech, swallowing and teeth?
- How often will I be checked, and for how long?
- Will I need a prosthesis or reconstruction, and who will provide it?
- Should I see a dentist before treatment starts?
- Is there a speech and language therapist or dietitian on the team?
- Who should I call if I notice a new lump or ulcer between appointments?
- Can my case be reviewed at a specialist head and neck centre?
Resources
- Antonescu, C.R. et al. (2011) ‘EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland’, Genes, Chromosomes and Cancer, 50(7), pp. 559-570.
- Desai, A. et al. (2022) ‘Clear cell carcinoma: a comprehensive literature review of 254 cases’, International Journal of Oral and Maxillofacial Surgery, 51(6), pp. 705-712.
- Weinreb, I. (2013) ‘Hyalinizing clear cell carcinoma of salivary gland: a review and update’, Head and Neck Pathology, 7(Suppl 1), pp. S20-S29.
- Xu, B. et al. (2025) ‘Hyalinizing clear cell carcinoma of the head and neck: a multicenter retrospective study of 87 cases focusing on prognostic pathologic features and grading scheme’, Modern Pathology, 38(11), 100834.
- National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.